3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
7
fludarabine
4
Nivolumab
4
Cyclophosphamide
4
Radiation
3
Interleukin-2
3
talimogene laherparepvec
2
poly ICLC
2
budigalimab
2
aldesleukin
2
Radiotherapy
2
Ipilimumab
2
Everolimus
2
CTLA-4 Antigen
2
zimberelimab
1
venetoclax
1
veliparib
1
vatalanib
1
tocilizumab
1
temsirolimus
1
rovalpituzumab tesirine
1
prednylidene
1
pentetreotide
1
lorvotuzumab mertansine
1
glucopyranosyl lipid-A
1
flt3 ligand protein
1
deltacortene
1
cixutumumab
1
avelumab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Merkel Cell
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled